CAS: 64664-99-9; 2-Oxo-7-(((2S,3R,4S,5R,6R)-3,4,5-Trihydroxy-6-(Hydroxymethyl)Tetrahydro-2H-Pyran-2-yl)Oxy)-2H-Chromene-3-Carboxylic Acid

该化合物是合成玻璃板,作为酶-galactosidase的基质;该化合物的特点是其结构,其中包括与一个carboxyumbelliferyry集团相连的星际阳性表面,其存在具有荧光特性,使该碳化纤维素组在生物化学实验中发挥作用,用于检测-gallactosidose活动;在酶进行水解后,释放出荧光微电子素,可定量测量,以便评估酶活动;CUG在水中通常溶解,在标准实验室条件下表现出稳定性;其应用范围扩大到分子生物学和生物化学学,特别是在涉及酶动能学和细胞过程的研究中;此外,由于其荧光性特性,它经常被用于各种成像技术和实验,有助于其在研究和诊断应用中的效用.

英文名称2-Oxo-7-(((2S,3R,4S,5R,6R)-3,4,5-Trihydroxy-6-(Hydroxymethyl)Tetrahydro-2H-Pyran-2-yl)Oxy)-2H-Chromene-3-Carboxylic Acid
中文名称7-β-半乳糖香豆素-3-羧酸
IUPAC名称2-oxo-7-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-2H-chromene-3-carboxylic acid
其它别名3-Carboxyumbelliferyl-b-D-galactopyranoside; 7-b-Galactosylcoumarin-3-carboxylicacid
CAS编号64664-99-9
MFCD编号:MFCD00153934
分子式:C16H16O10
分子量:368.29
产品CID: 1630234
产品分类生物化工 → 糖类化合物 → 单糖

相似结构搜索
InChIKey: HGMXXIAQZWTZLR-WUGLTUCPSA-N
InChI=1S/C16H16O10/c17-5-10-11(18)12(19)13(20)16(26-10)24-7-2-1-6-3-8(14(21)22)15(23)25-9(6)4-7/h1-4,10-13,16-20H,5H2,(H,21,22)/t10-,11+,12+…
计算化学: 氢键受体数10.0氢键供体数5.0可旋转键数4.0

MSDS等安全信息

警示词Warning
危险描述H302-H315-H319-
防范说明P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P501-
安全声明22-24/25
WGK Germany3

合成工艺路线路线简述

海关参考信息

2905122000-异丙醇
2905310000-1,2-乙二醇
2905320000-1,2-丙二醇
2905399001-1,3-丙二醇
💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
详情请参考：📖 海关编码查询和海关进出口税则

专利信息

专利号:US-2019154696-A1
优先权日:2015-08-31
标题 :Colorimetric Labeling and Detection Methods and Compositions
发明人：CLARKE SCOTT; GEE KYLE; FINNESSY CARMEN
权利人:LIFE TECHNOLOGIES CORP
摘要:The present disclosure provides methods, compositions and kits for measuring cellular nascent nucleic acid synthesis by colorimetric labeling of nucleic acid. The nucleic acid synthesis can be measured as cell proliferation, DNA or RNA synthesis, gene expression or apoptosis. Additionally, these methods may be used to screen compounds for their effect on cellular proliferation by treating cells or an organism with the test compound simultaneous to or before treatment with a competitive nucleoside analog.